Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)

NCT01686815 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01686815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01686815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Completed
Start date
October 31, 2012
Completion date
May 31, 2016
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glucose metabolism, insulin resistance, metabolic syndrome, schizophrenia, serious mental illness